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Introduction {#sec001}
============

Long QT syndrome (LQTS) is a disorder of the heart's electrical activity that infrequently causes severe ventricular arrhythmias such as a type of ventricular tachycardia called torsade de pointes (TdP) and ventricular fibrillation, which can be fatal. LQTS are categorized into 2 groups: inherited (genetic) and acquired \[[@pone.0164309.ref001]\]. Acquired LQTS is caused by specific drugs, hypokalemia, or hypomagnesemia. Drug-induced LQTS can be caused by a variety of drugs; not only anti-arrhythmic drugs but also other non-cardiac drugs such as antipsychotics, antibiotics and anti-allergic drugs \[[@pone.0164309.ref001]\]. The International Council for Harmonization published "Guidance for industry E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs" in October 2005 \[[@pone.0164309.ref002]\]. Furthermore, the U.S. Food and Drug Administration (FDA) released a safety announcement "Azithromycin and the risk of potentially fatal heart rhythms" in May 2013. The Japanese Circulation Society joint study group published "Guidelines for Diagnosis and Management of Patients with Long QT Syndrome and Brugada Syndrome" in 2012 \[[@pone.0164309.ref001]\]. The Ministry of Health, Labour and Welfare in Japan released "The manual for handling disorders due to adverse drug reactions", which is focused on ventricular tachycardia, in May 2009 \[[@pone.0164309.ref003]\]. Drug-induced LQTS are estimated to occur at rates of approximately 2.0--8.8% among patients prescribed anti-arrhythmic drugs and thousandth or millionth part of those prescribed non-cardiac drugs \[[@pone.0164309.ref001],[@pone.0164309.ref004]--[@pone.0164309.ref006]\]. Since LQTS is a rare adverse event, epidemiologic research on the risk factors of LQTS is fraught with difficulties. Spontaneous reporting systems (SRSs), wherein clinicians report their concerns about potential drug-induced adverse events during their normal diagnostic assessments of patients, are useful for the detection of rare and severe adverse events. SRSs have been recognized as primary tools for pharmacovigilance that reflect the realities of clinical practice. In the analysis of SRS reports, data mining algorithms have been utilized to identify drug-associated adverse events by disproportionality analysis. The reporting odds ratio (ROR) has been developed for use with SRS data as a measure of the relative risk for drug-associated adverse events \[[@pone.0164309.ref007],[@pone.0164309.ref008]\].

The regulatory authority in Japan, the Pharmaceuticals and Medical Devices Agency (PMDA), has released national SRS data via the Japanese Adverse Drug Event Report (JADER) database. We assessed the risk of drug-induced LQTS for prescription drugs by analyzing data obtained from the JADER database. To evaluate signals of adverse drug reactions, we used the ROR, which is commonly used in pharmacovigilance studies. It has recently been proposed that modeling the time-to-onset of adverse drug reactions could be a useful adjunct to signal detection based on relative risk \[[@pone.0164309.ref009],[@pone.0164309.ref010]\]. The Weibull shape parameter (WSP) test has been suggested as a new method for the analysis of time-to-onset data without the need for a reference population \[[@pone.0164309.ref011]\]. The WSP can describe the varying incidence of adverse events and is used to evaluate hazard functions for detecting adverse events. There have been no previous published reports on time-to-onset analyses for LQTS using SRS data. The aims of this study were to assess the time-to-onset and ROR of LQTS according to drug treatment.

Materials and Methods {#sec002}
=====================

Adverse events recorded in the JADER database from April 2004 to May 2016 were downloaded from the PMDA website ([www.pmda.go.jp](http://www.pmda.go.jp)). The JADER database consists of 4 data tables: patient demographics information, drug information, adverse events, and primary illness. We built a relational database that integrated the 4 data tables using File Maker Pro 13 software (FileMaker, Santa Clara, CA, USA). In the "drug information" table of the JADER database, each drug was assigned a code according to its association with adverse drug reactions: "suspected drug", "concomitant drug", or "interacting drug." The analysis was restricted to reports where drugs were recorded as a "suspected drug."

The adverse events in this study relied on the definition provided by the Medical Dictionary for Regulatory Activities (MedDRA, <http://www.meddra.org/>) ver. 19.0. We have selected preferred terms (PTs) according to Standardized MedDRA Queries (SMQs). SMQs were built by the Maintenance and Support Services Organization. SMQs are groupings of PTs according to the level that relates to a defined medical condition, and the included terms may relate to signs, symptoms, diagnoses, syndromes, physical findings, laboratory and other physiologic test data, etc \[[@pone.0164309.ref012]\]. The grouping of SMQs allows for useful data retrieval and the presentation of relevant individual case safety reports. SMQs usually contain two categories of PTs corresponding to a "narrow" scope and a "broad" scope. Those two categories, "narrow" and "broad," allow for the identification of cases that are highly likely to represent the condition of interest (a "narrow" scope) and those that would be useful when a user seeks to identify all possible cases, including some that may prove to be of little or no interest on closer inspection (a "broad" scope). The "narrow" scope yields "specificity", while the "broad" search yields "sensitivity." A "broad" scope includes both the "narrow" terms and the additional "broad" terms, which are often of a less-specific nature \[[@pone.0164309.ref012]\].

For evaluation with a "broad" scope, we utilized 20 PTs that matched the SMQ for *torsade de pointes/QT prolongation* (SMQ code: 20000001). Next, we evaluated for a "narrow" scope by utilizing a limited number of PTs that matched the same SMQ. The number of selected PTs categorized in the "narrow" scope was 6, as follows: electrocardiogram QT interval abnormal (PT code: 10063748), electrocardiogram QT prolonged (PT code: 10014387), long QT syndrome (PT code: 10024803), long QT syndrome congenital (PT code: 10057926), torsade de pointes (PT code: 10044066), and ventricular tachycardia (PT code: 10047302).

Furthermore, the possibility that drugs could shorten QT and pose safety concerns has recently become a subject of active debate \[[@pone.0164309.ref013],[@pone.0164309.ref014]\]. Poluzzi *et al*. defined torsadogenicity according to the following criteria: 1) torsade de pointes, 2) QT interval abnormalities, 3) ventricular fibrillation/tachycardia, and 4) sudden cardiac death \[[@pone.0164309.ref015]\]. In their results, all drugs in groups 1 or 2 demonstrated a high ROR value. According to Poluzzi's report, we selected the PTs according to groups 1 \[torsade de pontes (PT code: 10044066)\] and 2 \[electrocardiogram QT prolonged (PT code: 10014387), long QT syndrome (PT code: 10024803), long QT syndrome congenital (PT code: 10057926), electrocardiogram QT interval abnormal (PT code: 10063748), electrocardiogram QT shortened (PT code: 10014388), electrocardiogram U-wave abnormality (PT code: 10055032), electrocardiogram U-wave biphasic (Low Level Term (LLT) code: 10055068), electrocardiogram repolarization abnormality (PT code: 10052464), and electrocardiogram R on T phenomenon (PT code: 10048883)\].

Iribarren *et al*. analyzed 90 drugs \[[@pone.0164309.ref016]\]. They selected drugs according to the Arizona Center for Education & Research on Therapeutics website ([www.azcert.org](http://www.azcert.org), <https://crediblemeds.org>) as having QT liability \[[@pone.0164309.ref013]\] and added carbamazepine, primidone, phenytoin, digoxin, lidocaine, and aripiprazole, which were not listed on the Arizona Center for Education & Research on Therapeutics website \[[@pone.0164309.ref014]\]. In this study, we selected 113 drugs in combination with the drugs analyzed by Iribarren *et al*. and according to the Japanese regulatory authority's guidance and manual \[[@pone.0164309.ref001],[@pone.0164309.ref003]\] ([Table 1](#pone.0164309.t001){ref-type="table"}). Our lists include antiarrhythmic drugs and also some non-cardiac drugs.
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###### Number of reports and Reporting Odds Ratio of Long QT syndrome.

![](pone.0164309.t001){#pone.0164309.t001g}

  Therapeutic category                             Subclassification             Drugs                 Total (n)   SMQ: whole   SMQ: narrow   g1+g2 [^b^](#t001fn002){ref-type="table-fn"}                                                                                                                                     
  ------------------------------------------------ ----------------------------- --------------------- ----------- ------------ ------------- ---------------------------------------------- ----------------------------------------- ------ -------- ------ ----------------------------------------- ------ -------- ------ -----------------------------------------
                                                                                                       404450      9823         394627        2.4                                                                                      2732   401718   0.7                                              2002   402448   0.5    
  Anti-arrhythmic drug                             class I                       Aprindine             274         46           228           16.8                                           8.1 (5.9--11.2)                           38     236      13.9   24.0 (17.0--33.9)                         29     245      10.6   24.1 (16.4--35.5)
                                                                                 Cibenzoline           749         142          607           19.0                                           9.5 (7.9--11.4)                           87     662      11.6   19.9 (15.9--25.0)                         46     703      6.1    13.4 (9.9--18.2)
                                                                                 Disopyramide          363         127          236           35.0                                           21.9 (17.6--27.2)                         113    250      31.1   69.3 (55.3--86.8)                         92     271      25.3   71.5 (56.2--90.9)
                                                                                 Flecainide            123         55           68            44.7                                           32.7 (22.9--46.6)                         37     86       30.1   64.1 (43.5--94.4)                         14     109      11.4   26.0 (14.9--45.4)
                                                                                 Lidocaine             927         91           836           9.8                                            4.4 (3.5--5.5)                            20     907      2.2    3.3 (2.1--5.1)                            5      922      0.5    1.1 (0.5--2.6)
                                                                                 Mexiletine            436         29           407           6.7                                            2.9 (2.0--4.2)                            14     422      3.2    4.9 (2.9--8.4)                            7      429      1.6    3.3 (1.6--6.9)
                                                                                 Pilsicainide          648         271          377           41.8                                           29.7 (25.3--34.7)                         162    486      25.0   52.0 (43.4--62.4)                         45     603      6.9    15.3 (11.3--20.8)
                                                                                 Pirmenol              46          31           15            67.4                                           83.3 (44.9--154.3)                        27     19       58.7   211.0 (117.2--380.0)                      21     25       45.7   170.6 (95.4--305.3)
                                                                                 Procainamide          34          11           23            32.4                                           19.2 (9.4--39.5)                          11     23       32.4   70.6 (34.4--145.0)                        10     24       29.4   84.2 (40.2--176.3)
                                                                                 Quinidine             4           0            4             0.0                                                                                      0      4        0.0                                              0      4        0.0    
                                                   class III                     Amiodarone            1663        193          1470          11.6                                           5.4 (4.6--6.2)                            166    1497     10.0   17.3 (14.7--20.4)                         137    1526     8.2    19.3 (16.1--23.1)
                                                                                 Nifekalant            97          70           27            72.2                                           104.9 (67.3--163.6)                       61     36       62.9   254.8 (168.5--385.4)                      55     42       56.7   270.7 (180.7--405.4)
                                                                                 Sotalol               105         32           73            30.5                                           17.7 (11.7--26.8)                         23     82       21.9   41.6 (26.1--66.1)                         9      96       8.6    18.9 (9.5--37.5)
                                                   class IV                      Bepridil              640         365          275           57.0                                           55.3 (47.3--64.8)                         327    313      51.1   174.4 (148.6--204.6)                      293    347      45.8   198.7 (168.9--233.7)
  Cardiotonic drug                                                               Digoxin               439         62           377           14.1                                           6.6 (5.1--8.7)                            41     398      9.3    15.4 (11.1--21.2)                         25     414      5.7    12.3 (8.2--18.4)
  Cardiotonic drug/antasthmatic                                                  Epinephrine           5           0            5             0.0                                                                                      0      5        0.0                                              0      5        0.0    
  Beta blocker                                                                   Atenolol              338         40           298           11.8                                           5.4 (3.9--7.5)                            13     325      3.8    5.9 (3.4--10.3)                           11     327      3.3    6.8 (3.7--12.4)
  Antipsychotics                                   antimanic drug                Lithium               1068        24           1044          2.2                                            0.9 (0.6--1.4)                            9      1059     0.8    1.3 (0.6--2.4)                            7      1061     0.7    1.3 (0.6--2.8)
                                                   atypical antipsychotic        Clozapine             1062        39           1023          3.7                                            1.5 (1.1--2.1)                            13     1049     1.2    1.8 (1.1--3.2)                            13     1049     1.2    2.5 (1.4--4.3)
                                                                                 Quetiapine            1893        87           1806          4.6                                            1.9 (1.6--2.4)                            24     1869     1.3    1.9 (1.3--2.8)                            17     1876     0.9    1.8 (1.1--3.0)
                                                                                 Ziprasidone           1           0            1             0.0                                                                                      0      1        0.0                                              0      1        0.0    
                                                   banzamide                     Sulpiride             1366        80           1286          5.9                                            2.5 (2.0--3.2)                            62     1304     4.5    7.1 (5.5--9.2)                            58     1308     4.2    9.1 (7.0--11.9)
                                                   butyrophenone drug            Haloperidol           1311        97           1214          7.4                                            3.2 (2.6--4.0)                            39     1272     3.0    4.6 (3.3--6.3)                            37     1274     2.8    5.9 (4.3--8.2)
                                                   phenothiazine antipsychotic   Chlorpromazine        1240        70           1170          5.6                                            2.4 (1.9--3.1)                            23     1217     1.9    2.8 (1.8--4.2)                            20     1220     1.6    3.3 (2.1--5.2)
                                                                                 Levomepromazine       781         63           718           8.1                                            3.5 (2.7--4.6)                            18     763      2.3    3.5 (2.2--5.6)                            15     766      1.9    4.0 (2.4--6.6)
                                                                                 Prochlorperazine      123         3            120           2.4                                            1.0 (0.3--3.2)                            2      121      1.6    −[^†^](#t001fn003){ref-type="table-fn"}   1      122      0.8    −[^†^](#t001fn003){ref-type="table-fn"}
                                                                                 Thioridazine          46          2            44            4.3                                            −[^†^](#t001fn003){ref-type="table-fn"}   1      45       2.2    −[^†^](#t001fn003){ref-type="table-fn"}   1      45       2.2    −[^†^](#t001fn003){ref-type="table-fn"}
                                                   SSRI                          Citaropram            0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Fluoxetine            0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Paroxetine            2677        95           2582          3.5                                            1.5 (1.2--1.8)                            30     2647     1.1    1.7 (1.2--2.4)                            28     2649     1.0    2.1 (1.5--3.1)
                                                                                 Sertraline            976         52           924           5.3                                            2.3 (1.7--3.0)                            17     959      1.7    2.6 (1.6--4.2)                            16     960      1.6    3.4 (2.1--5.5)
                                                                                 Venlafaxine           31          1            30            3.2                                            −[^†^](#t001fn003){ref-type="table-fn"}   0      31       0.0                                              0      31       0.0    
                                                   tricyclic antidepresants      Amitriptyline         330         21           309           6.4                                            2.7 (1.8--4.3)                            9      321      2.7    4.1 (2.1--8.0)                            7      323      2.1    4.4 (2.1--9.2)
                                                                                 Clomipramine          335         21           314           6.3                                            2.7 (1.7--4.2)                            5      330      1.5    2.2 (0.9--5.4)                            5      330      1.5    3.1 (1.3--7.4)
                                                                                 Desipramine           0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Doxepin               0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Imipramine            264         16           248           6.1                                            2.6 (1.6--4.3)                            3      261      1.1    1.7 (0.5--5.3)                            1      263      0.4    −[^†^](#t001fn003){ref-type="table-fn"}
                                                                                 Nortriptyline         39          8            31            20.5                                           10.4 (4.8--22.6)                          3      36       7.7    12.3 (3.8--39.9)                          2      37       5.1    −[^†^](#t001fn003){ref-type="table-fn"}
                                                                                 Protriptyline         0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Trimipramine          4           2            2             50.0                                           −[^†^](#t001fn003){ref-type="table-fn"}   0      4        0.0                                              0      4        0.0    
                                                   others                        Aripiprazole          1895        84           1811          4.4                                            1.9 (1.5--2.3)                            20     1875     1.1    1.6 (1.0--2.4)                            19     1876     1.0    2.0 (1.3--3.2)
                                                                                 Olanzapine            1749        105          1644          6.0                                            2.6 (2.1--3.1)                            33     1716     1.9    2.9 (2.0--4.0)                            26     1723     1.5    3.1 (2.1--4.5)
                                                                                 Pimozide              44          5            39            11.4                                           5.2 (2.0--13.1)                           5      39       11.4   18.9 (7.4--47.9)                          4      40       9.1    20.1 (7.2--56.3)
                                                                                 Risperidone           2604        125          2479          4.8                                            2.0 (1.7--2.4)                            33     2571     1.3    1.9 (1.3--2.7)                            31     2573     1.2    2.4 (1.7--3.5)
  Antibiotics                                                                    Azithromycin          1235        60           1175          4.9                                            2.1 (1.6--2.7)                            29     1206     2.3    3.6 (2.5--5.2)                            25     1210     2.0    4.2 (2.8--6.2)
                                                                                 Ciprofloxacin         737         14           723           1.9                                            0.8 (0.5--1.3)                            9      728      1.2    1.8 (0.9--3.5)                            7      730      0.9    1.9 (0.9--4.1)
                                                                                 Clarithromycin        3318        145          3173          4.4                                            1.8 (1.6--2.2)                            100    3218     3.0    4.7 (3.8--5.8)                            89     3229     2.7    5.8 (4.6--7.1)
                                                                                 Co-trimoxazole        0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Erythromycin          175         8            167           4.6                                            1.9 (0.9--3.9)                            7      168      4.0    6.1 (2.9--13.1)                           3      172      1.7    3.5 (1.1--11.0)
                                                                                 Fluconazole           344         18           326           5.2                                            2.2 (1.4--3.6)                            17     327      4.9    7.7 (4.7--12.5)                           14     330      4.1    8.6 (5.0--14.7)
                                                                                 Garenoxacin           1618        75           1543          4.6                                            2.0 (1.6--2.5)                            31     1587     1.9    2.9 (2.0--4.1)                            27     1591     1.7    3.4 (2.3--5.1)
                                                                                 Gatifloxacin          266         4            262           1.5                                            0.6 (0.2--1.6)                            1      265      0.4    −[^†^](#t001fn003){ref-type="table-fn"}   1      265      0.4    −[^†^](#t001fn003){ref-type="table-fn"}
                                                                                 Itraconazole          1178        20           1158          1.7                                            0.7 (0.4--1.1)                            12     1166     1.0    1.5 (0.9--2.7)                            10     1168     0.8    1.7 (0.9--3.2)
                                                                                 Ketoconazole          12          0            12            0.0                                                                                      0      12       0.0                                              0      12       0.0    
                                                                                 Levofloxacin          3293        52           3241          1.6                                            0.6 (0.5--0.8)                            25     3268     0.8    1.1 (0.8--1.7)                            22     3271     0.7    1.4 (0.9--2.1)
                                                                                 Moxifloxacin          607         72           535           11.9                                           5.4 (4.2--7.0)                            30     577      4.9    7.7 (5.3--11.2)                           28     579      4.6    9.8 (6.7--14.4)
                                                                                 Ofloxacin             104         3            101           2.9                                            1.2 (0.4--3.8)                            0      104      0.0                                              0      104      0.0    
                                                                                 Pentamidine           245         15           230           6.1                                            2.6 (1.6--4.4)                            12     233      4.9    7.6 (4.3--13.6)                           9      236      3.7    7.7 (3.9--15.0)
                                                                                 Voriconazole          925         31           894           3.4                                            1.4 (1.0--2.0)                            22     903      2.4    3.6 (2.4--5.5)                            18     907      1.9    4.0 (2.5--6.4)
  Antineoplastic agent                                                           Arsenic trioxide      397         106          291           26.7                                           14.8 (11.8--18.5)                         104    293      26.2   54.2 (43.2--68.0)                         99     298      24.9   70.2 (55.7--88.5)
                                                                                 Crizotinib            793         33           760           4.2                                            1.7 (1.2--2.5)                            27     766      3.4    5.2 (3.6--7.7)                            27     766      3.4    7.2 (4.9--10.5)
                                                                                 Dasatinib             917         24           893           2.6                                            1.1 (0.7--1.6)                            19     898      2.1    3.1 (2.0--4.9)                            19     898      2.1    4.3 (2.7--6.8)
                                                                                 Nilotinib             1520        138          1382          9.1                                            4.1 (3.4--4.8)                            126    1394     8.3    13.9 (11.5--16.7)                         126    1394     8.3    19.3 (16.0--23.3)
                                                                                 Octreotide            402         6            396           1.5                                            0.6 (0.3--1.4)                            0      402      0.0                                              0      402      0.0    
                                                                                 Pazopanib             729         15           714           2.1                                            0.8 (0.5--1.4)                            6      723      0.8    1.2 (0.5--2.7)                            6      723      0.8    1.7 (0.7--3.7)
                                                                                 Tamoxifen             655         7            648           1.1                                            0.4 (0.2--0.9)                            7      648      1.1    1.6 (0.8--3.4)                            7      648      1.1    2.2 (1.0--4.6)
  Anti-ulcer drug                                  H2 recepter antagonist        Cimetidine            189         3            186           1.6                                            0.6 (0.2--2.0)                            2      187      1.1    −[^†^](#t001fn003){ref-type="table-fn"}   2      187      1.1    −[^†^](#t001fn003){ref-type="table-fn"}
                                                                                 Famotidine            3168        87           3081          2.7                                            1.1 (0.9--1.4)                            67     3101     2.1    3.2 (2.5--4.1)                            63     3105     2.0    4.2 (3.2--5.4)
  Anticonvulsant                                   Antiepileptic drug            Carbamazepine         4917        95           4822          1.9                                            0.8 (0.6--1.0)                            9      4908     0.2    0.3 (0.1--0.5)                            8      4909     0.2    0.3 (0.2--0.7)
                                                                                 Primidone             25          2            23            8.0                                            −[^†^](#t001fn003){ref-type="table-fn"}   0      25       0.0                                              0      25       0.0    
                                                   others                        Lamotrigine           2794        43           2751          1.5                                            0.6 (0.5--0.8)                            6      2788     0.2    0.3 (0.1--0.7)                            6      2788     0.2    0.4 (0.2--1.0)
                                                                                 Levetiracetam         957         18           939           1.9                                            0.8 (0.5--1.2)                            2      955      0.2    −[^†^](#t001fn003){ref-type="table-fn"}   2      955      0.2    −[^†^](#t001fn003){ref-type="table-fn"}
                                                                                 Phenytoin             1487        33           1454          2.2                                            0.9 (0.6--1.3)                            9      1478     0.6    0.9 (0.5--1.7)                            7      1480     0.5    1.0 (0.5--2.0)
  Alzheimer\'s type dementia treatment drug                                      Donepezil             1631        202          1429          12.4                                           5.8 (5.0--6.7)                            83     1548     5.1    8.1 (6.5--10.1)                           77     1554     4.7    10.3 (8.2--13.0)
                                                                                 Galantamine           481         55           426           11.4                                           5.2 (3.9--6.9)                            6      475      1.2    1.9 (0.8--4.2)                            6      475      1.2    2.5 (1.1--5.7)
  Overactive bladder treatment drug                antispasmodic                 Solifenacin           663         25           638           3.8                                            1.6 (1.1--2.4)                            16     647      2.4    3.7 (2.2--6.0)                            15     648      2.3    4.7 (2.8--7.8)
  Antasthmatic                                     LABA                          Salmeterol            596         11           585           1.8                                            0.8 (0.4--1.4)                            1      595      0.2    −[^†^](#t001fn003){ref-type="table-fn"}   1      595      0.2    −[^†^](#t001fn003){ref-type="table-fn"}
                                                   SABA                          Metaproterenol        0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Albuterol             0           0            0                                                                                                      0      0                                                         0      0               
                                                   others                        Terbutaline           0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Levalbuterol          0           0            0                                                                                                      0      0                                                         0      0               
  Antiemetic                                                                     Dolasetron            0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Ondansetron           21          0            21            0.0                                                                                      0      21       0.0                                              0      21       0.0    
  Antihistamine drug                                                             Diphenhydramine       97          2            95            2.1                                            −[^†^](#t001fn003){ref-type="table-fn"}   0      97       0.0                                              0      97       0.0    
                                                                                 Fexofenadine          531         25           506           4.7                                            2.0 (1.3--3.0)                            6      525      1.1    1.7 (0.8--3.8)                            6      525      1.1    2.3 (1.0--5.2)
                                                                                 Hydroxyzine           350         34           316           9.7                                            4.3 (3.0--6.2)                            11     339      3.1    4.8 (2.6--8.7)                            9      341      2.6    5.3 (2.7--10.3)
  Antiobesity                                                                    Fenfluramine          0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Phentermine           0           0            0                                                                                                      0      0                                                         0      0               
                                                                                 Sibutramine           0           0            0                                                                                                      0      0                                                         0      0               
  Cold medicine                                                                  Ephedrine             123         22           101           17.9                                           8.8 (5.5--13.9)                           7      116      5.7    8.9 (4.1--19.1)                           4      119      3.3    6.8 (2.5--18.3)
                                                                                 Phenylpropanolamine   5           0            5             0.0                                                                                      0      5        0.0                                              0      5        0.0    
                                                                                 Pseudoephedrine       60          3            57            5.0                                            2.1 (0.7--6.8)                            0      60       0.0                                              0      60       0.0    
  Antiparkinson                                                                  Amantadine            844         25           819           3.0                                            1.2 (0.8--1.8)                            6      838      0.7    1.1 (0.5--2.4)                            6      838      0.7    1.4 (0.6--3.2)
  Stimulant drug                                                                 Amphetamine           0           0            0                                                                                                      0      0                                                         0      0               
  Antiretroviral / protease inhibitor                                            Atazanavir            311         2            309           0.6                                            −[^†^](#t001fn003){ref-type="table-fn"}   0      311      0.0                                              0      311      0.0    
  ADHD treatment drug                                                            Atomoxetine           111         6            105           5.4                                            2.3 (1.0--5.2)                            1      110      0.9    −[^†^](#t001fn003){ref-type="table-fn"}   1      110      0.9    −[^†^](#t001fn003){ref-type="table-fn"}
  Lipid-lowering agent                                                           Atorvastatin          2424        33           2391          1.4                                            0.6 (0.4--0.8)                            7      2417     0.3    0.4 (0.2--0.9)                            7      2417     0.3    0.6 (0.3--1.2)
  Sedative                                                                       Chloral hydrate       29          0            29            0.0                                                                                      0      29       0.0                                              0      29       0.0    
  Antimalarial drug                                                              Chloroquine           0           0            0                                                                                                      0      0                                                         0      0               
  Gastrointestinal prokinetic agent                                              Cisapride             1           0            1             0.0                                                                                      0      1        0.0                                              0      1        0.0    
  Diuretic                                                                       Indapamide            201         7            194           3.5                                            1.4 (0.7--3.1)                            2      199      1.0    −[^†^](#t001fn003){ref-type="table-fn"}   2      199      1.0    −[^†^](#t001fn003){ref-type="table-fn"}
  Antihypertensive drug                                                          Isradipine            0           0            0                                                                                                      0      0                                                         0      0               
  Cancer pain drug                                                               Methadone             29          5            24            17.2                                           8.4 (3.2--22.0)                           5      24       17.2   30.7 (11.7--80.5)                         5      24       17.2   42.0 (16.0--110.1)
  Narcolepsy treatment drugs/ADHD treatment drug                                 Methylphenidate       376         13           363           3.5                                            1.4 (0.8--2.5)                            4      372      1.1    1.6 (0.6--4.2)                            2      374      0.5    −[^†^](#t001fn003){ref-type="table-fn"}
  Antihypotensive drug                                                           Midodorine            32          1            31            3.1                                            −[^†^](#t001fn003){ref-type="table-fn"}   1      31       3.1    −[^†^](#t001fn003){ref-type="table-fn"}   1      31       3.1    −[^†^](#t001fn003){ref-type="table-fn"}
  Antihypertensive drug                                                          Nicardipine           293         18           275           6.1                                            2.6 (1.6--4.2)                            0      293      0.0                                              0      293      0.0    
  Adrenergic agents                                                              Phenylephrine         90          8            82            8.9                                            3.9 (1.9--8.1)                            2      88       2.2    −[^†^](#t001fn003){ref-type="table-fn"}   1      89       1.1    −[^†^](#t001fn003){ref-type="table-fn"}
  Antihyperlipidemic drug                                                        Probucol              63          22           41            34.9                                           21.6 (12.9--36.3)                         18     45       28.6   59.2 (34.2--102.4)                        18     45       28.6   81.1 (46.9--140.4)
  Immunosuppressant                                                              Tacrolimus            8052        30           8022          0.4                                            0.1 (0.1--0.2)                            4      8048     0.0    0.1 (0.0--0.2)                            1      8051     0.0    −[^†^](#t001fn003){ref-type="table-fn"}
  Antiallergic drug                                                              Terfenadine           0           0            0                                                                                                      0      0                                                         0      0               
  α-2 adrenergic agonist / muscle relaxant                                       Tizanidine            271         13           258           4.8                                            2.0 (1.2--3.5)                            6      265      2.2    3.3 (1.5--7.5)                            4      267      1.5    3.0 (1.1--8.1)
  Overactive bladder treatment drug                                              Tolterodine           106         2            104           1.9                                            −[^†^](#t001fn003){ref-type="table-fn"}   0      106      0.0                                              0      106      0.0    
  Phosphodiesterase inhibitor                                                    Vardenafil            27          3            24            11.1                                           5.0 (1.5--16.7)                           0      27       0.0                                              0      27       0.0    

^a^ RR: Reporting Ratio,

^b^ PTs according to group1 and 2 defined by Poluzzi *et al*.,

^†^ Number of cases ≤2.

Among these selected drugs, anti-arrhythmic drugs were categorized using the Vaughan--Williams classification system.

For signal detection, we calculated the ROR as the ratio of the odds of reporting an adverse event (LQTS), *versus* all other events for a given drug, compared to the reporting odds for all other drugs in the JADER database. RORs were expressed as point estimates with a 95% confidence interval (CI). Safety signals were considered significant when the lower limit of the 95% CI of the estimated ROR was greater than 1 \[[@pone.0164309.ref007]\].

The median, quartiles, and WSP were used for evaluation of the time-to-onset data \[[@pone.0164309.ref009],[@pone.0164309.ref010]\]. Time-to-onset data was calculated from the start date of administration to the occurrence of the specific adverse events. It is necessary to take right truncation into account when estimating the time-to-onset of adverse events from SRS data. We chose an analysis period of 65 days after the start of administration to focus attention on the onset of adverse events within 2 months after the drug administration. The rate of occurrence of adverse events after prescription is thought to depend on the causal mechanism and will often vary over time; in contrast, adverse events not associated with the drug will occur at a constant background rate. The WSP test is used for statistical analysis of time-to-onset data and can describe the non-constant ratio of incidence of adverse events \[[@pone.0164309.ref010],[@pone.0164309.ref011],[@pone.0164309.ref017]\]. The shape parameter β of the Weibull distribution has been used to indicate the level of hazard over time without a reference population. Accordingly, in this study, when β was equal to 1, the hazard was considered to be constant over time. When β was lower than 1, the hazard was considered to decrease over time. In contrast, when β was greater than 1, the hazard was considered to increase over time \[[@pone.0164309.ref009]--[@pone.0164309.ref011],[@pone.0164309.ref017]\].

All data analyses were performed using JMP 11.0 (SAS Institute, Cary, NC, USA).

Results {#sec003}
=======

The JADER database contained 404,450 reports from April 2004 to May 2016. The number of case reports extracted by searching using the SMQ for *torsade de pointes/QT prolongation* (SMQ code: 20000001) with PTs matching a "narrow" scope, a "broad" scope, and the PTs selected by Iribarren *et al*. were 9,823 (2.4%), 2,732 (0.7%), and 2,002 (0.5%), respectively. The number of case reports, reporting ratio, and ROR including 95% CI for each drug are summarized in [Table 1](#pone.0164309.t001){ref-type="table"}.

In the "narrow" scope, the RORs (95% CI) for male and female subjects were 0.79 (0.74--0.86) and 1.28 (1.19--1.38), respectively. The numbers of case reports of bepridil, amiodarone, pilsicainide, nilotinib, disopyramide, arsenic trioxide, clarithromycin, cibenzoline, donepezil, famotidine, sulpiride, and nifekalant were 327 (51.1%), 166 (10.0%), 162 (25.0%), 126 (8.3%), 113 (31.1%), 104 (26.2%), 100 (3.0%), 87 (11.6%), 83 (5.1%), 67 (2.1%), 62 (4.5%), and 61 (62.9%), respectively. The RORs (95% CI) for these drugs were 174.4 (148.6--204.6), 17.3 (14.7--20.4), 52.0 (43.4--62.4), 13.9 (11.5--16.7), 69.3 (55.3--86.8), 54.2 (43.2--68.0), 4.7 (3.8--5.8), 19.9 (15.9--25.0), 8.1 (6.5--10.1), 3.2 (2.5--4.1), 7.1 (5.5--9.2), and 254.8 (168.5--385.4), respectively. The 95% CI lower limit of these drugs significantly exceeded 1, and so the signal for association with LQTS was considered to be significant for these drugs.

The time-to-onset data and WSP analyses are summarized in [Table 2](#pone.0164309.t002){ref-type="table"}.

10.1371/journal.pone.0164309.t002

###### The medians and weibull parameter of each drugs.

![](pone.0164309.t002){#pone.0164309.t002g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Therapeutic category            Drugs                                                   Case reports[^a^](#t002fn001){ref-type="table-fn"}   Median (day) (25%-75%)                      Scale parameter                            Shape parameter
  ------------------------------- ---------------------------- -------------------------- ---------------------------------------------------- ------------------------------------------- ------------------------------------------ -----------------
  Anti-arrhythmic drug            Total (oral)                                            258                                                  11.0 (3.0--31.3)                            21.3 (18.5--24.3)                          1.0 (0.9--1.1)

                                  disopyramide (oral)          17                         3.0 (1.0--22.0)                                      9.3 (4.0--20.5)                             0.7 (0.4--0.9)                             

  flecainide (oral)               14                           9.0 (4.8--12.5)            13.0 (8.0--20.7)                                     1.3 (0.8--1.8)                                                                         

  pilsicainide (oral)             39                           4.0 (3.0--24.0)            12.9 (8.4--19.4)                                     0.8 (0.7--1.1)                                                                         

  cibenzoline (oral)              21                           5.0 (2.0--10.5)            10.1 (5.8--17.0)                                     0.9 (0.6--1.2)                                                                         

  aprindine (oral)                16                           20.0 (11.0--35.8)          20.5 (12.8--31.9)                                    1.3 (0.8--1.8)                                                                         

  amiodarone (oral)               23                           3.0 (0.0--12.0)            13.7 (6.5--27.6)                                     0.8 (0.5--1.1)                                                                         

  bepridil (oral)                 128                          18.0 (6.0--43.0)           30.7 (26.6--35.3)                                    1.4 (1.2--1.6)                                                                         

  Total (i.v.)                                                 80                         0.0 (0.0--1.0)                                       2.7 (1.8--3.8)                              1.0 (0.8--1.2)                             

                                  pilsicainide (i.v.)          14                         0.0 (0.0--0.0)                                       --[^†^](#t002fn002){ref-type="table-fn"}    --[^†^](#t002fn002){ref-type="table-fn"}   

  amiodarone (i.v.)               20                           0.0 (0.0--1.8)             3.3 (1.4--7.3)                                       0.9 (0.6--1.4)                                                                         

  nifekalant (i.v.)               37                           1.0 (0.0--1.0)             2.6 (1.6--4.2)                                       1.0 (0.7--1.3)                                                                         

  others (i.v.)                   9                            0.0 (0.0--0.5)             1.7 (0.8--3.7)                                       3.5 (0.8--9.3)                                                                         

   disopyramide (i.v.)\           3\                           0.0 (0.0--0.0)\            --[^†^](#t002fn002){ref-type="table-fn"}\            --[^†^](#t002fn002){ref-type="table-fn"}\                                              
   flecainide (i.v.)\             3\                           0.0 (0.0--0.0)\            --[^†^](#t002fn002){ref-type="table-fn"}\            --[^†^](#t002fn002){ref-type="table-fn"}\                                              
   cibenzoline (i.v.)\            2\                           0.5 (0.0--1.0)\            --[^†^](#t002fn002){ref-type="table-fn"}\            --[^†^](#t002fn002){ref-type="table-fn"}\                                              
   aprindine (i.v.)\              1\                           2.0 (2.0--2.0)\            --[^†^](#t002fn002){ref-type="table-fn"}\            --[^†^](#t002fn002){ref-type="table-fn"}\                                              

  Digitalis preparation                                        digoxin (oral)             5                                                    9.0 (3.0--24.5)                             17.6 (4.3--70.2)                           1.2 (0.4--2.6)

  digoxin (i.v.)                  1                            1.0 (1.0--1.0)             --[^†^](#t002fn002){ref-type="table-fn"}             --[^†^](#t002fn002){ref-type="table-fn"}                                               

  Antipsychotics                  Total                                                   47                                                   10.0 (3.0--19.0)                            16.9 (12.3--22.8)                          1.1 (0.8--1.3)

                                  haloperidol (oral or i.m.)   5                          16.0 (8.0--49.0)                                     36.9 (18.9--70.0)                           2.1 (0.8--4.4)                             

  haloperidol (i.v.)              8                            11.0 (3.0--19.0)           10.4 (3.6--28.2)                                     0.9 (0.4--1.6)                                                                         

  olanzapine (oral or i.m.)       7                            10.0 (2.0--29.0)           16.0 (6.7--36.2)                                     1.2 (0.6--2.1)                                                                         

  paroxetine (oral)               6                            3.5 (0.8--47.8)            17.3 (3.2--84.0)                                     0.7 (0.3--1.3)                                                                         

  sulpiride (oral)                11                           10.0 (8.0--27.0)           18.7 (9.7--34.6)                                     1.1 (0.7--1.8)                                                                         

  risperidone (oral)              10                           11.5 (1.0--16.0)           11.2 (6.2--19.5)                                     1.4 (0.7--2.4)                                                                         

  Antibiotics                                                  clarithromycin (oral)      37                                                   7.0 (3.0--21.0)                             13.5 (9.7--18.6)                           1.1 (0.9--1.5)

  garenoxacin (oral)              24                           3.0 (1.0--4.0)             3.5 (2.7--4.3)                                       2.2 (1.5--3.0)                                                                         

  moxifloxacin (oral)             27                           0.0 (0.0--6.0)             6.8 (3.8--11.7)                                      1.1 (0.7--1.6)                                                                         

  Anti-ulcer drug                                              famotidine (oral)          11                                                   10.0 (2.0--20.0)                            16.7 (7.8--34.1)                           1.0 (0.6--1.5)

  famotidine (i.v.)               6                            10.5 (2.3--30.3)           20.7 (7.7--52.8)                                     1.2 (0.5--2.2)                                                                         

  Anticancer drug                                              arsenic trioxide (i.v.)    50                                                   11.0 (4.0--18.8)                            14.7 (11.3--18.9)                          1.2 (0.9--1.5)

  nilotinib (oral)                27                           8.0 (2.0--18.0)            15.4 (10.9--21.3)                                    1.4 (1.0--1.9)                                                                         

  Curative drug for Alzheimer's                                donepezil (oral or i.n.)   13                                                   14.0 (1.5--30.0)                            17.0 (8.3--33.1)                           1.0 (0.6--1.5)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Number of reports used for analysis.

^†^ Number of cases with different time-to-onset durations ≤3.

The median and quartiles of anti-arrhythmic drugs (oral) and anti-arrhythmic drugs (intravenous) were 11.0 (3.0--31.3) and 0.0 (0.0--1.0) days, respectively. The median and the quartiles of aprindine (oral) and bepridil were 20.0 (11.0--35.8) and 18.0 (6.0--43.0) days, respectively. The time-to-onset profiles are demonstrated in Figs [1](#pone.0164309.g001){ref-type="fig"}--[4](#pone.0164309.g004){ref-type="fig"}.

![Histogram and Weibull Shape Parameter of Long QT Syndrome for 1) Disopyramide (oral), 2) Flecainide (oral), 3) Pilsicainide (oral), 4) Cibenzoline (oral), 5) Aprindine (oral), 6) Amiodarone (oral), 7) Bepridil (oral).](pone.0164309.g001){#pone.0164309.g001}

![Histogram and Weibull Shape Parameter of Long QT Syndrome for 1) Amiodarone (i.v.), 2) Nifekalant (i.v.).](pone.0164309.g002){#pone.0164309.g002}

![Histogram and Weibull Shape Parameter of Long QT Syndrome for 1) Haloperidol (oral or i.m.), 2) Haloperidol (i.v.), 3) Olanzapine (oral or i.m.), 4) Paroxetine (oral), 5) Sulpiride (oral), 6) Risperidone (oral).](pone.0164309.g003){#pone.0164309.g003}

![Histogram and Weibull Shape Parameter of Long QT Syndrome for 1) Digoxin (oral), 2) Clarithromycin (oral), 3) Garenoxacin (oral), 4) Moxifloxacin (oral), 5) Famotidine (oral), 6) Famotidine (i.v.), 7) Arsenic trioxide (i.v.), 8) Nilotinib (oral), 9) Donepezil (oral or i.n.).](pone.0164309.g004){#pone.0164309.g004}

The WSP β and 95% CI lower limit of bepridil exceeded 1, indicating a significant association of bepridil with LQTS.

Discussion {#sec004}
==========

The high frequency and unpredictability of drug-induced LQTS are important issues for clinicians. The most common cause of drug-induced LQTS is inhibition of the cardiac hERG potassium channel \[[@pone.0164309.ref018],[@pone.0164309.ref019]\]. It has been known that several anti-arrhythmic drugs also have a risk of causing a pro-arrhythmic effect \[[@pone.0164309.ref020]\], which is a problem that has been reported in clinical practice \[[@pone.0164309.ref003]\]. Our analysis showed that all of the anti-arrhythmic drugs we evaluated had high and significant RORs in the "narrow" scope ([Table 1](#pone.0164309.t001){ref-type="table"}). In particular, anti-arrhythmic drugs belonging to Vaughan*--*Williams classification category 3, which have a K channel blocking action and are used when other anti-arrhythmic drugs are not effective, had especially high RORs. The occurrence rates of ventricular tachycardia (including TdP) described in the packaging inserts of pilsicainide, aprindine, and bepridil are "0.31%", "0.20%", and "0.20%", respectively. For nifekalant, the occurrence rate of ventricular tachycardia (including TdP) is described as "more than 5%". In comparison with other anti-arrhythmic drugs, the LQTS risk of nifekalant might be high. Upon further consideration of the mechanism (cardiac hERG potassium channel inhibitory effect) underlying QT prolongation, the high ROR of nifekalant that we detected was assumed to be a plausible result.

Drug-induced LQTS has led to withdrawals or restrictions on the use of a number of marketed drugs over the last decade, especially non-cardiovascular drugs \[[@pone.0164309.ref021],[@pone.0164309.ref022]\]. In our analysis, significant RORs were detected for 34 non-cardiovascular drugs, including pimozide, arsenic trioxide, nilotinib, donepezil, ephedrine, methadone, probucol, etc. ([Table 1](#pone.0164309.t001){ref-type="table"}). These 34 drugs have been reported to potentially cause QT prolongation by several studies \[[@pone.0164309.ref016],[@pone.0164309.ref023]--[@pone.0164309.ref025]\]. The results obtained by analysis of data from the JADER database in this study were reasonable in the context of those reported in the literature. For bepridil, amiodarone, nilotinib, arsenic trioxide, and nifekalant, warnings about the risk of LQTS or ventricular tachycardia including TdP are described in the warning boxes of their package inserts in Japanese.

The risk of LQTS is known to be increased by many factors, including: female gender, cardiac hypertrophy, chronic heart failure, cardiomyopathies, electrolyte imbalance (hypokalemia and hypomagnesemia), polypharmacy, race, etc. \[[@pone.0164309.ref021],[@pone.0164309.ref022]\]. Gender was reported as both a demographic and systematic risk factor of LQTS \[[@pone.0164309.ref003],[@pone.0164309.ref021],[@pone.0164309.ref022]\]. A potential interaction of quinidine with gender was reported \[[@pone.0164309.ref026],[@pone.0164309.ref027]\]. The RORs in female subjects were higher than those in male subjects were. A reduced cardiac repolarization reserve closely related to sex steroids has been proposed to explain the higher propensity of women to develop drug-induced LQTS \[[@pone.0164309.ref022]\]. Polypharmacy giving rise to drug-drug interactions should also be considered as a risk factor for drug-induced LQTS \[[@pone.0164309.ref022],[@pone.0164309.ref028]--[@pone.0164309.ref030]\]. For the majority of drugs except for class IA drugs, LQTS risk increases with the dose prescribed \[[@pone.0164309.ref019]\]. The results of a retrospective analysis of the FDA Adverse Event Reporting System database (FAERS) by Shaffer *et al*., where concomitant risk factors for QT prolongation and TdP occurring in association with the administration of macrolide antimicrobials were examined, showed that the co-administration of drugs prolonging the QT interval accounts for 50% of registered TdP reports \[[@pone.0164309.ref031]\]. Pharmacokinetic interactions with drugs, such as thioridazine, erythromycin, and terfenadine, that are known to inhibit cytochrome P450 isozyme CYP3A4 can enhance the LQTS risk of these agents by decreasing their clearance \[[@pone.0164309.ref003],[@pone.0164309.ref019]\]. Elderly female patients with polypharmacy including drugs with the potential to inhibit drug-elimination mechanisms are at a particularly increased risk. Certain drugs (e.g., diuretics that cause hypokalemia) inhibit drugs elimination \[[@pone.0164309.ref021]\]. The acquired factor of age might influence the ROR. More detailed analysis focusing on these factors is a subject for future investigation.

Curtis and colleagues have evaluated the concomitant use of QT prolonging drugs in a cohort of 1.1 million patients. The concomitant use of 2 QT prolonging drugs or a QT prolonging drug and a drug that inhibits its clearance was identified in 9.4% of patients, and the concomitant use of ≥ 3 drugs was observed in 0.7% of patients \[[@pone.0164309.ref032]\]. We surveyed the co-administration frequencies among 113 drugs in this study. From the evaluation utilizing the SMQ with a "narrow" scope, we obtained frequencies as follows for monotherapy with anti-arrhythmic drugs \[aprindine (31.6% \[12/38\]), disopyramide (73.5% \[83/113\]), cibenzoline (82.8% \[72/87\]), nifekalant (88.5% \[54/61\]), pilsicainide (87.7% \[142/162\]), and bepridil (75.5% \[247/327\])\] and antipsychotics \[haloperidol (25.6% \[10/39\]), chlorpromazine (17.4% \[4/23\]), and sulpiride (48.4% \[30/62\])\]. From these data, it seems that the frequency of co-administration of anti-arrhythmic drugs with other drugs that could potentially induce LQTS was high. On the contrary, it seems that the frequency of co-administration of antipsychotics with other drugs was low. Despite being a potent antiarrhythmic and causing prolongation of the QT interval, amiodarone appears to be associated with a low frequency of pro-arrhythmic events \[[@pone.0164309.ref033]\]. In our study, the number of reports and the ROR of amiodarone were relatively high. We do not have a conclusive explanation for these data. We could consider that the co-administration of amiodarone and other drug(s) partially explains the high values. We did not examine the potential drug-by-drug bias because there were too few cases for the robust further analysis of time-to-onset.

Several studies with the FAERS database, which is an SRS database, have demonstrated significant associations between LQTS and certain suspected drugs \[[@pone.0164309.ref015],[@pone.0164309.ref034],[@pone.0164309.ref035]\]. The FAERS database is a computerized SRS information system to which healthcare professionals and consumers send adverse event reports voluntarily through the MedWatch program. Poluzzi *et al*. evaluated antipsychotics and torsadogenic risk using the FAERS database and identified 3 torsadogenic signals for amisulpride, cyamemazine, and olanzapine, which were neither mentioned by the 2011 AZCERT classifications nor arose from previous literature data \[[@pone.0164309.ref015]\]. Validation and risk quantification through different sources such as healthcare databases are generally recommended in the evaluation of SRS data \[[@pone.0164309.ref015]\]. The torsadogenic risks of oral antihistamines and antipsychotics were evaluated by combining the FAERS database with drug utilization data across Europe \[[@pone.0164309.ref034],[@pone.0164309.ref035]\]. Based on the JADER database, Ikeno *et al*. reported a relationship between antipsychotics and the cardiac adverse events of QT prolonged and TdP \[[@pone.0164309.ref036]\]. Significant RORs for associations of the antipsychotic drugs haloperidol and sulpiride with LQTS were observed in our study.

To the best of our knowledge, no time-to-onset analyses for drug-induced LQTS have been systematically addressed using SRSs. Although the analysis strategy carries the inherent limitations of SRS data, the aim of our time-to-onset analysis was to obtain new information and compare the relative risks and onset profiles of LQTS for prescription drugs.

Generally, anti-arrhythmic drugs that inhibit the hERG potassium channel cause electrophysiological changes immediately following administration, and LQTS and TdP occur a few days later except for specific drugs, such as probucol and bepridil \[[@pone.0164309.ref003]\]. In the time-to-onset analysis, the medians of times-to-onset for anti-arrhythmic drugs (intravenous) were within 1 day of each other. Special attention should be paid to the possibility of LQTS onset with these drugs and careful observation is recommended from soon after administration until 1--2 days, especially for the intravenous route of administration. The profiles of aprindine and bepridil were different from those of other anti-arrhythmic drugs ([Table 2](#pone.0164309.t002){ref-type="table"}, Figs [1](#pone.0164309.g001){ref-type="fig"} and [2](#pone.0164309.g002){ref-type="fig"}). According to the package inserts and interview forms, the half-lives of drug elimination for aprindine (50 h) and bepridil (80 h) are longer than those for other anti-arrhythmic drugs (2--13.4 h). It has been reported that the LQTS risk of bepridil often increases depending on time \[[@pone.0164309.ref003]\]. The medians times-to-onset for aprindine (oral) and bepridil (oral) were 20 and 18 days, respectively ([Table 2](#pone.0164309.t002){ref-type="table"}). The WSP β of bepridil was 1.4 (1.2--1.6) and so the hazard was considered to increase over time ([Table 2](#pone.0164309.t002){ref-type="table"}). The medians times-to-onset for antipsychotics and arsenic trioxide were 10.0 and 11.0 days, respectively ([Table 2](#pone.0164309.t002){ref-type="table"}). These results corresponded with those of previous reports and confirmed the necessity of long-term observation after the administration of these drugs.

In acquired LQTS, latent genetic backgrounds may be related to the prolongation of the QT interval \[[@pone.0164309.ref037],[@pone.0164309.ref038]\]. Five to nineteen percent of patients with drug-induced torsade de pointes carry mutations in genes involved in congenital long QT syndrome \[[@pone.0164309.ref039],[@pone.0164309.ref040]\]. For congenital LQTS, as many as 13 distinct genetic mutations have been identified \[[@pone.0164309.ref041]\]. Several potassium voltage-gated channel subfamily H member 2 (*KCNH2*) mutations were identified in persons with drug-induced arrhythmias in a database of SRS for adverse drug reactions \[[@pone.0164309.ref042]\]. Recently, pharmacokinetic and pharmacodynamic influencing polymorphisms related to drug-induced QT interval prolongation have been detected by genome-wide association studies \[[@pone.0164309.ref038],[@pone.0164309.ref043]\]. The frequencies of polymorphisms in genes known to be associated with congenital long QT syndrome had varying distributions among ethnic groups \[[@pone.0164309.ref038]\]. Caucasians seem to be more sensitive to QT prolongation than other ethnicities \[[@pone.0164309.ref038]\]. Our analysis did not consider this genetic factor because the JADER database lacks detailed clinical information \[[@pone.0164309.ref044]\]. Thus, typical of results obtained from analysis using SRS databases, our results require further epidemiological studies for confirmation.

In our results, the RORs of several drugs such as nifekalant, bepridil, pirmenol, etc. had huge values (\> 100) in the case of analysis with the PTs group of the "narrow" scope or with the PTs group of "g1 + g2" compared to the results with the "broad" scope ([Table 1](#pone.0164309.t001){ref-type="table"}). The calculated RORs might vary significantly depending on the selection of PTs.

Electrocardiography (ECG) is an important criterion for the diagnosis of torsade de pointes/QT prolongation. Iribarren *et al*. have assessed the drug-induced alteration of QT interval in a self-controlled crossover study using a large ECG database \[[@pone.0164309.ref016]\]. Since detailed patient information such as ECG is not intrinsically included in the JADER database, we did not evaluate ECG results in this study.

In this study, we selected PTs for the identification of torsade de pointes/QT prolongation, which is coded according to the terminology prescribed by the MedDRA. According to the Introductory Guide MedDRA Version 19.0, each PT is a distinct descriptor (a single medical concept) for a symptom, sign, disease, diagnosis, therapeutic indication, investigation, surgical, or medical procedure, or a medical, social, or family history characteristic \[[@pone.0164309.ref045]\]. PTs should be unambiguous and as specific and self-descriptive as possible in the context of international requirements. Therefore, eponymous terms are only used when they are recognized internationally. The granularity/specificity of the PT level is such that clinical pathologic or etiologic qualifiers of the descriptors are represented at the PT level (<http://www.meddra.org/sites/default/files/guidance/file/intguide_19_0_english.pdf>) \[[@pone.0164309.ref045]\]. The JADER database is derived from spontaneous volunteer reporting. The contributors only report adverse events according to ICH E2B, the international safety reporting guidelines, and rely on the definitions provided by MedDRA. It was difficult to confirm the criteria used to define torsade de pointes/QT prolongation events by volunteers at the time of reporting. However, the reports in the JADER database have been reported by healthcare "professionals." Furthermore, our analysis was restricted to reports where drugs were recorded as a "suspected drug". We consider that these data suggest the association of certain drugs with torsade de pointes/QT prolongation, but further validation of these associations is needed.

The SRS is subject to various biases, including the exclusion of healthy individuals, the lack of a denominator, and confounding factors \[[@pone.0164309.ref008]\]. The ROR is defined as the ratio of reported cases of a defined adverse event of interest versus all other adverse events for the drug of interest, compared to the reporting odds for all other drugs present in the database. In basic terms, the higher the ROR value, the stronger the risk of an adverse event appears to be. In absolute terms, the ROR indicates an increased risk of adverse event reporting, and not a risk of adverse event occurrence. The ROR is different from the "odds ratio" (OR) that is commonly used in epidemiological studies. Because of these deficits within the SRS, the ROR does not allow for risk quantification. Rather, the ROR offers a rough indication of the strength of the signal and relates only to the hypothesis \[[@pone.0164309.ref008]\]. This should be strengthened in pharmacovigilance studies.

In evaluations of the risk of LQTS, unadjusted confounding factors should be taken into account. The ROR is a clear, easy to understand, and applicable technique, which allows the control of covariates through logistic regression analysis \[[@pone.0164309.ref046]--[@pone.0164309.ref048]\]. However, we did not perform further analyses to obtain adjusted RORs for age, gender, and other comorbidities. The reasons were as follows: 1) the number of reports was several dozen to several hundred at most, and 2) the JADER database does not always contain enough patient background information to properly evaluate an event. Therefore, it seemed to be difficult to apply the logistic regression analysis to adjusting cofactors in this study. The covariates should be evaluated with respect to a variety of patients' backgrounds in well-organized epidemiologic studies in the future.

Despite the inherent limitations of SRS data, the results we obtained about the association between suspected drugs and LQTS are in agreement with the results of previous reports. Our analysis of time-to-onset data indicated that the time-to-onset profiles of LQTS differed among drugs. This information may be useful for clinicians and patients to prevent sudden death following LQTS and implement more efficient therapeutic plans.

Conclusion {#sec005}
==========

Our study assessed time-to-onset data for LQTS obtained from the JADER database. The results indicated that the profiles of LQTS onset differed among drugs. Our findings corresponded with those of previous reports and confirmed the necessity of long-term observation after administration, especially for specific drugs such as bepridil and aprindine. This information may be useful for the prevention of sudden death following LQTS and for efficient therapeutic planning.
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